This study is testing a new treatment approach for women with metastatic triple-negative breast cancer (TNBC) that has already been treated with standard chemotherapy. The study will first give you bortezomib injections. If your cancer progresses, you will then receive pembrolizumab and cisplatin injections. Researchers believe bortezomib might make your cancer more sensitive to pembrolizumab and cisplatin. The main goal is to see how many patients have their tumors shrink or disappear (objective response rate) with this treatment, measured over 18 months. The study is looking for about 20 participants and its current status is unclear.

Study design

This is an interventional study with a planned enrollment of 20 women. It is testing a sequence of treatments: bortezomib followed by pembrolizumab and cisplatin.

What's involved

You will receive bortezomib injections until your disease progresses, then pembrolizumab and cisplatin injections for up to 6 cycles or until disease progression. Biopsies of a metastatic lesion will be taken at the start of the study and if your disease progresses on bortezomib.

Compensation

Not stated in the trial record.

Follow-up

The primary outcome of objective response rate will be measured at 18 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.